CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a US-Ireland specialty pharmaceutical company, has announced the appointment of Rayna Sethi Herman as Chief Commercial Officer (CCO). Rayna will play a key role in the commercial advancement of Shorla’s pipeline of specialty oncology drugs, including the growth of Nelarabine Injection which was launched in May, and the launch of Jylamvo in the US market, an oncology and autoimmune drug that the Company acquired in October..

马萨诸塞州剑桥市（商业新闻）——美国爱尔兰专业制药公司Shorla Oncology（“Shorla”）宣布任命Rayna Sethi Herman为首席商务官（CCO）。Rayna将在Shorla专业肿瘤药物管道的商业发展中发挥关键作用，包括5月份推出的奈拉滨注射液的增长，以及该公司10月份收购的肿瘤和自身免疫药物Jylamvo在美国市场的推出。。

Rayna brings to Shorla more than 30 years of expertise in commercialization and has launched more than 20 biopharmaceutical products in her career. Most recently, she served as CCO at EVERSANA, the leading provider of commercial services to the life sciences industry. During her tenure, Rayna launched oncology and rare disease products through EVERSANA’s Complete Commercialization Program.

Rayna为Shorla带来了30多年的商业化专业知识，并在其职业生涯中推出了20多种生物制药产品。最近，她在EVERSANA担任首席财务官，EVERSANA是生命科学行业商业服务的领先供应商。在任职期间，雷娜通过EVERSANA的完整商业化计划推出了肿瘤学和罕见病产品。

Prior to joining EVERSANA, she built and sold Health Strategies Group, a firm that was the leading provider of market access insights for biopharma executives..

在加入EVERSANA之前，她建立并出售了Health Strategies Group，这是一家为生物制药高管提供市场准入见解的领先公司。。

Rayna has also held roles of varying responsibility at Merck & Co. and sits on the board of advisors at Almaden Genomics.

雷娜还曾在默克公司（Merck＆Co.）担任不同的职责，并担任阿尔马登基因组公司（Almaden Genomics）的顾问委员会成员。

“We are delighted to have Rayna join our team,” said Sharon Cunningham, Chief Executive Officer at Shorla Oncology. “We are at an important moment in our growth, and her leadership will be instrumental in the continued advancement of our product portfolio and strengthening of our position as an established specialty US Oncology company.

Shorla Oncology首席执行官莎伦·坎宁安（SharonCunningham）表示：“我们很高兴雷娜加入我们的团队。“我们正处于成长的重要时刻，她的领导将有助于继续推进我们的产品组合，巩固我们作为美国既定专业肿瘤学公司的地位。

We are confident that her expertise will contribute significantly to our ongoing efforts to bring differentiated and essential treatments to patients in need.”.

我们相信，她的专业知识将为我们正在进行的努力做出重大贡献，为有需要的患者带来差异化和必要的治疗。”。

The news comes shortly after Shorla announced that it has raised $35 million in Series B funding to accelerate the growth of its growing portfolio of oncology drugs. This year, Shorla also announced the US approval and launch of Nelarabine Injection and the acquisition and imminent launch of Jylamvo Oral Solution..

这一消息发布不久前，Shorla宣布已筹集3500万美元的B系列资金，以加速其不断增长的肿瘤药物组合的增长。今年，Shorla还宣布美国批准并推出奈拉滨注射液，以及收购并即将推出Jylamvo口服液。。

“I am thrilled to be joining Shorla Oncology as Chief Commercial Officer,' said Rayna Sethi Herman. 'Having worked alongside the Shorla team at EVERSANA, I have seen firsthand their commitment to bringing therapies to market that will address drug shortages and improve the preparation and adherence of oncology medication.

“我很高兴能加入Shorla Oncology担任首席商务官，”Rayna Sethi Herman说。“与EVERSANA的Shorla团队一起工作，我亲眼看到他们致力于将治疗方法推向市场，以解决药物短缺问题，并改善肿瘤药物的制备和依从性。

I am inspired by the team and the quality of their products and I look forward to leading the company’s commercialization efforts and bringing its much-needed treatments to market.”.

我受到团队和他们产品质量的鼓舞，我期待着领导公司的商业化努力，并将其急需的治疗方法推向市场。”。

About Shorla Oncology

关于Shorla肿瘤学

Established in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Oncology is a privately held, US- and Ireland based specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for orphan and pediatric cancers. The company concentrates on indications where existing treatments are limited, in shortage, or the drug applications are inadequate for the target population.

Shorla Oncology由Sharon Cunningham和Orlaith Ryan于2018年成立，是一家美国和爱尔兰的私营专业制药公司，拥有针对孤儿和儿科癌症的先进创新肿瘤药物管道。该公司专注于现有治疗方法有限，短缺或药物应用不足以满足目标人群的适应症。

Shorla's growing portfolio brings accessible, affordable and life-saving differentiated treatments to patients, delivering a major contribution to patient care..

Shorla不断增长的投资组合为患者带来了可获得的，负担得起的和挽救生命的差异化治疗，为患者护理做出了重大贡献。。